Interferon-α enhances CD95L-induced apoptosis of human malignant glioma cells

Journal of Neuroimmunology

Volumn 87, Issue 1-2, 1998, Pages 121-129

  Roth, Wilfried ^a   Wagenknecht, Bettina ^a   Dichgans, Johannes ^a   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

BCL 2; Caspase; CD95; Glioma; IFN ; Synergy

Indexed keywords

ALPHA INTERFERON; FAS ANTIGEN; FAS LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; GLIOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TARGET CELL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CARMUSTINE; CASPASE 3; CASPASES; CELL MEMBRANE; CYSTEINE ENDOPEPTIDASES; DRUG SYNERGISM; GENE EXPRESSION; GENES, BCL-2; GLIOMA; HUMANS; INTERFERON-ALPHA; TUMOR CELLS, CULTURED;

EID: 0032127022     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00079-4     Document Type: Article

References (33)

1. Buckner, J.C., Brown, L.D., Kugler, J.W., Cascino, T.L., Krook, J.E., Mailliard, J.A., Kardinal, G.G., Tschetter, L.K., O'Fallon, J.R., Scheithauer, B.W., 1995. Phase II evaluation of recombinant Interferon alpha and BCNU in recurrent glioma. J. Neurosurg. 82, 430-435.
2. Egle, A., Villunger, A., Kos, M., Bock, G., Gruber, J., Auer, B., Greil, R., 1996. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur. J. Immunol. 26, 3119-3126.
3. Enari, M., Hug, H., Nagata, S., 1995. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375, 78-81.
4. Färkkila, M., Jääskeläinen, J., Kallio, M., Blomstedt, G., Raininko, R., Virkkunen, P., Paetau, A., Sarelin, H., Mantyla, M., 1994. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br. J. Cancer 70, 138-141.
5. Fetell, M.R., Housepian, E.M., Oster, M.W., Cote, D.N., Sisti, M.B., Marcus, S.G., Fisher, P.B., 1990. Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study. Cancer 65, 78-83.
6. Fine, H.A., 1995. Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol. Clin. 13, 827-846.
7. Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M., Canellos, G.P., 1993. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597.
8. Garrison, J.I., Berens, M.E., Shapiro, J.R., Treasurywala, S., Floyd Smith, G., 1996. Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines. J. Neuro-Oncol. 30, 213-223.
9. Gratas, C., Tohma, Y., Van Meir, E.G., Klein, M., Tenan, M., Ishii, N., Tachibana, O., Kleihues, P., Ohgaki, H., 1997. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7, 863-869.
10. Lesser, G.J., Grossman, S., 1994. The chemotherapy of high-grade astrocytomas. Semin. Oncol. 21, 220-235.
11. Mizuno, M., Yoshida, J., Sugita, K., Inoue, I., Seo, H., Hayashi, Y., Koshizaka, T., Yagi, K., 1990. Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res. 50, 7826-7829.
12. Moulton, T.A., Jiang, H., Guarini, L., Fetell, M.R., Fisher, P.B., 1992. Induction of growth suppression and modification of gene expression in multi-drug-resistant human glioblastoma multiforme cells by recombinant human fibroblast and immune interferon. Int. J. Cancer 51, 373-378.
13. Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.M., Peter, M.E., Dixit, V.M., 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-I) death-inducing signaling complex. Cell 85, 817-827.
14. Naidu, K.A., Wiranowska, M., Phuphanich, S., Prockop, L.D., 1996. Modulation of glioma cell growth and 5-lipoxygenase expression by interferon. Anticancer Res. 16, 3475-3482.
15. Ogasawara, J., Watanabe Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., Nagata, S., 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809.
16. Rensing Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S.M., Weller, M., Aebischer, P., Krammer, P.H., Fontana, A., 1995. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25, 2253-2258.
17. Roth, W., Fontana, A., Trepel, M., Reed, J.C., Dichgans, J., Weller, M., 1997. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother. 44, 55-63.
18. Roth, W., Wagenknecht, B., Grimmel, C., Dichgans, J., Weller, M., 1998. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells. Association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br. J. Cancer 77, 404-411.
19. Saas, P., Walker, P.R., Hahne, M., Quiquerez, A.L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.G., de Tribolet, N., Tschopp, J., Dietrich, P.Y., 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J. Clin. Invest. 99, 1173-1178.
20. Selleri, C., Sato, T., Del Vecchio, L., Luciano, L., Barrett, A.J., Rotoli, B., Young, N.S., Maciejewski, J.P., 1997. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89, 957-964.
21. Wagenknecht, B., Gulbins, E., Lang, F., Dichgans, J., Weller, M., 1997. Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. FEBS Lett. 409, 17-23.
22. Webb, J.L., 1963. Effect of more than one inhibitor. In: Enzyme and Metabolic Inhibitors, Vol. 1. Academic Press, New York, pp. 66-79 and 487-512.
23. Weller, M., Fontana, A., 1995. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Rev. 21, 128-151.
24. Weller, M., Frei, K., Groscurth, P., Krammer, P.H., Yonekawa, Y., Fontana, A., 1994. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94, 954-964.
25. Weller, M., Malipiero, U., Aguzzi, A., Reed, J.C., Fontana, A., 1995a. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95, 2633-2643.
26. Weller, M., Malipiero, U., Rensing Ehl, A., Barr, P.J., Fontana, A., 1995b. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55, 2936-2944.
27. Weller, M., Weinstock, C., Will, C., Lang, F., Dichgans, J., Gulbins, E., 1997. CD95-dependent T cell killing by glioma cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol. Biochem. 7, 282-288.
28. Weller, M., Kleihues, P., Dichgans, J., Ohgaki, H., 1998. CD95 ligand: lethal weapon against malignant glioma? Brain Pathol 8, 285-293.
29. Yoshida, J., Kajita, Y., Wakabayashi, T., Sugita, K., 1994. Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir. 127, 55-59.
30. Yoshida, J., Wakabayashi, T., Mizuno, M., Sugita, K., Yoshida, T., Hori, S., Mori, T., Sato, T., Karashima, A., Kurisu, K. et al., 1992. Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J. Neurosurg. 77, 78-83.
31. Yung, W.K., Castellanos, A.M., Van Tassel, P., Moser, R.P., Marcus, S.G., 1990. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma. J. Neuro-Oncol. 9, 29-34.
32. Yung, W.K., Prados, M., Levin, V.A., Fetell, M.R., Bennett, J., Mahaley, M.S., Salcman, M., Etcubanas, E., 1991. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J. Clin. Oncol. 9, 1945-1949.
33. Zipp, F., Weller, M., Calabresi, P.A., Frank, J.A., Bash, C.N., Dichgans, J., McFarland, H.F., Martin, R., 1998. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing remitting multiple sclerosis. Ann. Neurol. 43, 116-120.